KalVista Pharmaceuticals (KALV) Tops Q2 EPS by 16c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q2 EPS of ($0.90), $0.16 better than the analyst estimate of ($1.06).

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
• Flowserve acquires Trillium valves division for $490 million
• Nike beats quarterly estimates as tariff recovery boosts profit